High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma

Long-term prognostic significance of response in multiple myeloma after stem cell transplantation

(2011) J. Martinez-Lopez et al.   BLOOD

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD

Comparison of Immunofixation, Serum Free Light Chain, and Immunophenotyping for Response Evaluation and Prognostication in Multiple Myeloma

(2011) Bruno Paiva et al.   JOURNAL OF CLINICAL ONCOLOGY

Importance of Achieving a Complete Response in Multiple Myeloma, and the Impact of Novel Agents

(2010) Asher A. Chanan-Khan et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

(2010) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Major Tumor Shrinking and Persistent Molecular Remissions After Consolidation With Bortezomib, Thalidomide, and Dexamethasone in Patients With Autografted Myeloma

(2010) Marco Ladetto et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of complete response in multiple myeloma

(2009) J.-L. Harousseau et al.   BLOOD

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

(2009) P. Kapoor et al.   BLOOD

Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in Total Therapy protocols

(2009) A. Hoering et al.   BLOOD

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

(2009) R Fonseca et al.   LEUKEMIA

Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation

(2008) B. Paiva et al.   BLOOD

Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma

(2008) Bart Barlogie et al.   CANCER

Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma

(2008) R A Kyle et al.   LEUKEMIA